Literature DB >> 21751957

Cytokines in neuroblastoma: from pathogenesis to treatment.

Vito Pistoia1, Giovanna Bianchi, Giacomo Borgonovo, Lizzia Raffaghello.   

Abstract

Cytokines released by cancer cells or by cells of the tumor microenvironment stimulate angiogenesis, act as autocrine or paracrine growth factors for malignant cells, promote tumor cell migration and metastasis or create an immunosuppressive microenvironment. These tumor-promoting effects of cytokines also apply to neuroblastoma (NB), a pediatric neuroectodermal malignancy with frequent metastatic presentation at diagnosis and poor prognosis. IL-6 and VEGF are the best characterized cytokines that stimulated tumor growth and metastasis, while others such as IFN-γ can exert anti-NB activity by inducing tumor cell apoptosis and inhibiting angiogenesis. On the other hand, cytokines are part of the anti-NB therapeutic armamentarium, as exemplified by IL-2 and granulocyte-macrophage colony stimulating factor that potentiate the activity of anti-NB antibodies. These recent results raise hope for more efficacious treatment of this ominous pediatric malignancy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21751957     DOI: 10.2217/imt.11.80

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  8 in total

1.  Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.

Authors:  Paola Bocca; Emma Di Carlo; Ignazio Caruana; Laura Emionite; Michele Cilli; Biagio De Angelis; Concetta Quintarelli; Annalisa Pezzolo; Lizzia Raffaghello; Fabio Morandi; Franco Locatelli; Vito Pistoia; Ignazia Prigione
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

2.  Low Dose of Bisphenol A Activates NF-κB/IL-6 Signals to Increase Malignancy of Neuroblastoma Cells.

Authors:  Shunjun Xiong; Yanjun Wang; Huijuan Li; Xiaofang Zhang
Journal:  Cell Mol Neurobiol       Date:  2016-11-19       Impact factor: 5.046

3.  Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.

Authors:  Rajen Mody; Arlene Naranjo; Collin Van Ryn; Alice L Yu; Wendy B London; Barry L Shulkin; Marguerite T Parisi; Sabah-E-Noor Servaes; Mitchell B Diccianni; Paul M Sondel; Julia G Bender; John M Maris; Julie R Park; Rochelle Bagatell
Journal:  Lancet Oncol       Date:  2017-05-23       Impact factor: 41.316

4.  Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma.

Authors:  Ruida Hou; Ying Yu; Madison N Sluter; Lexiao Li; Jiukuan Hao; Jie Fang; Jun Yang; Jianxiong Jiang
Journal:  Cell Rep       Date:  2022-06-21       Impact factor: 9.995

5.  Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.

Authors:  Emma Di Carlo; Paola Bocca; Laura Emionite; Michele Cilli; Giuseppe Cipollone; Fabio Morandi; Lizzia Raffaghello; Vito Pistoia; Ignazia Prigione
Journal:  Mol Ther       Date:  2013-03-12       Impact factor: 11.454

6.  Elevated TIMP-1 expression is associated with a prometastatic phenotype, disease relapse, and poor survival in neuroblastoma.

Authors:  Pritha Paul; Eric J Rellinger; Jingbo Qiao; Sora Lee; Natasha Volny; Chandrasekhar Padmanabhan; Carmelle V Romain; Bret Mobley; Hernan Correa; Dai H Chung
Journal:  Oncotarget       Date:  2017-07-28

7.  Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.

Authors:  Sascha Troschke-Meurer; Nikolai Siebert; Madlen Marx; Maxi Zumpe; Karoline Ehlert; Oliver Mutschlechner; Hans Loibner; Ruth Ladenstein; Holger N Lode
Journal:  Oncoimmunology       Date:  2019-09-08       Impact factor: 8.110

8.  A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

Authors:  M Fevzi Ozkaynak; Andrew L Gilman; Wendy B London; Arlene Naranjo; Mitchell B Diccianni; Sheena C Tenney; Malcolm Smith; Karen S Messer; Robert Seeger; C Patrick Reynolds; L Mary Smith; Barry L Shulkin; Marguerite Parisi; John M Maris; Julie R Park; Paul M Sondel; Alice L Yu
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.